- Home
- CARM vs KPRX Comparison
CARM vs KPRX Comparison
Compare CARM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- KPRX
- Stock Information
- Founded
- CARM 2016
- KPRX 1998
- Country
- CARM United States
- KPRX United States
- Employees
- CARM N/A
- KPRX N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CARM Health Care
- KPRX Health Care
- Exchange
- CARM Nasdaq
- KPRX Nasdaq
- Market Cap
- CARM 8.4M
- KPRX 9.1M
- IPO Year
- CARM N/A
- KPRX N/A
- Fundamental
- Price
- CARM $0.42
- KPRX $2.90
- Analyst Decision
- CARM Hold
- KPRX Strong Buy
- Analyst Count
- CARM 5
- KPRX 1
- Target Price
- CARM $0.90
- KPRX $10.00
- AVG Volume (30 Days)
- CARM 42.1M
- KPRX 1.3M
- Earning Date
- CARM 08-07-2025
- KPRX 08-08-2025
- Dividend Yield
- CARM N/A
- KPRX N/A
- EPS Growth
- CARM N/A
- KPRX N/A
- EPS
- CARM N/A
- KPRX N/A
- Revenue
- CARM $19,964,000.00
- KPRX $20,000.00
- Revenue This Year
- CARM N/A
- KPRX N/A
- Revenue Next Year
- CARM N/A
- KPRX N/A
- P/E Ratio
- CARM N/A
- KPRX N/A
- Revenue Growth
- CARM 32.45
- KPRX N/A
- 52 Week Low
- CARM $0.14
- KPRX $2.51
- 52 Week High
- CARM $1.90
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- CARM 52.02
- KPRX 43.33
- Support Level
- CARM $0.41
- KPRX $2.87
- Resistance Level
- CARM $0.56
- KPRX $3.22
- Average True Range (ATR)
- CARM 0.13
- KPRX 0.18
- MACD
- CARM -0.01
- KPRX -0.02
- Stochastic Oscillator
- CARM 20.33
- KPRX 5.77
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.